The diabetes epidemic: Can we stop the spread?

Pharmacotherapy

Volumn 23, Issue 10 II, 2003, Pages 1227-1231

  Haines, Stuart T ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

BEHAVIOR MODIFICATION; DIABETES MELLITUS; DISEASE CONTROL; EDITORIAL; EUROPE; GLUCOSE METABOLISM; HEALTH CARE MANAGEMENT; HEALTH CARE POLICY; HUMAN; OBESITY; PATIENT COUNSELING; PATIENT EDUCATION; PREVALENCE; TREATMENT OUTCOME; UNITED STATES;

DIABETES MELLITUS; HUMANS; LIFE STYLE; OBESITY; PATIENT EDUCATION; PHARMACEUTICAL SERVICES; PHARMACISTS; PROFESSIONAL ROLE; RISK FACTORS; UNITED STATES;

EID: 0141754114     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.12.1227.32708     Document Type: Editorial

References (31)

1. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-9.
2. Centers for Disease Control and Prevention. Diabetes program. Statistics-prevalence of diabetes by state. December 19, 2002. Available from http://www.cdc.gov/diabetes/statistics/prev/state/index.htm. Accessed on June 20, 2003.
3. Centers for Disease Control and Prevention. National diabetes statistics fact sheet: general information and national estimates on diabetes in the United States, 2000. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2002.
4. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
5. U.S. Department of Health and Human Services. HHS, ADA warn Americans of "pre-diabetes," encourage people to take healthy steps to reduce risks [press release]. Rockville, MD: U.S. Department of Health and Human Services; March 29, 2002. Available from http://www.hhs.gov/news/press/2002pres/20020327.html. Accessed on June 20, 2003.
6. Benjamin S, Valdez R, Geiss L, Rolka D, Narayan K. Estimated number of adults with prediabetes in the US in 2000. Diabetes Care 2003;26:645-9.
7. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7.
8. Shuldiner AR, Yang R, Gong DW. Resistin, obesity and insulin resistance-the emerging role of the adipocyte as an endocrine organ. N Engl J Med 2001;345:1345-6.
9. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12.
10. American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917-32.
11. Sironi AM, Vichi S, Gastaldelli A, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet 1998;352:837-53.
12. Hansson L, Zanchetti A, Carruthers S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet 1998;351:1755-62.
13. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramapril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
14. Goldberg R, Mellies M, Sacks F, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998;98:2513-19.
15. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
16. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. The Lancet 2003;361:2005-16.
17. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
18. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344: 1343-50.
19. Centers for Disease Control and Prevention. Team care: comprehensive lifetime management for diabetes. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 2001.
20. Koprosky J, Pretto Z, Poretsky L. Effects of an intervention by a diabetes team in hospitalized patients with diabetes. Diabetes Care 1997;20:1553-5.
21. Gaede P, Vedel P, Parving H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomized study. Lancet 1999;353:617-22.
22. Testa M, Simonson D. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus. JAMA 1998;280:1490-6.
23. Cranor CW, Bunting BA, Christensen DB. The Asheville project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003;43:173-84.
24. American Diabetes Association. Screening for type 2 diabetes [position statement]. Diabetes Care 2003;26(suppl 1):S21-4.
25. Carter B, Barnette D, Chrischilles E, Mazzotti G, Asali Z. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy 1997;17:1274-85.
26. Coast-Senior E, Kroner B, Kelly C, Trilli L. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother 1998;32:636-41.
27. Bluml B, McKenney J, Cziraky M. Pharmaceutical care services and results in project ImPACT: hyperlipidemia. J Am Pharm Assoc 2000;40:157-65.
28. Garrett DG, Martin LA. The Asheville project: participants' perceptions of factors contributing to the success of a patient self-management diabetes program. J Am Pharm Assoc 2003;43:185-90.
29. Cranor CW, Christensen DB. The Asheville project: factors associated with outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003;43:160-72.
30. Cranor CW, Christensen DB. The Asheville project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003;43:149-59.
31. Clark CJ, Fradkin J, Hiss R, Lorenz R. The national diabetes education program, changing the way diabetes is treated. Diabetes Care 2001;24:617-18.